Metabolic syndrome, C-reactive protein, and mortality in U.S. blacks and whites: The reasons for geographic and racial differences in Stroke (REGARDS) study

Takeki Suzuki, Jenifer Voeks, Neil A. Zakai, Nancy Swords Jenny, Todd M. Brown, Monika M. Safford, Martin LeWinter, George Howard, Mary Cushman

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: We evaluate associations of metabolic syndrome (MetS), C-reactive protein (CRP), and a CRP-incorporated definition of MetS (CRPMetS) with risk of all-cause mortality in a biracial population. RESEARCH DESIGN AND METHODS: We studied 23,998 participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort, an observational study of black and white adults ≥45 years old across the U.S. Elevated CRP was defined as ≥3 mg/L and MetS by therevised Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III; ATP III) criteria (three of five components). CRPMetS was defined as presence of three out of six components, with elevated CRP added to ATP III criteria as a sixth component. Cox models were used to calculate hazard ratios (HRs) for all-cause mortality, and population attributable risk (PAR) was calculated. Stratified analyses based on race and diabetes status were performed. RESULTS: There were 9,741 participants (41%) with MetS and 12,179 (51%) with CRPMetS at baseline. Over 4.8 years of follow-up, 2,050 participants died. After adjustment for multiple confounders, MetS, elevated CRP, and CRPMetS were each significantly associated with increased mortality risk (HRs 1.26 [95% CI 1.15-1.38], 1.55 [1.41-1.70], and 1.34 [1.22-1.48], respectively). The PAR was 9.5% for MetS, 18.1% for CRP, and 14.7% for CRPMetS. Associations of elevated CRP and of CRPMetS with mortality were significantly greater in whites than blacks, while no differences in associations were observed based on diabetes status. CONCLUSIONS: By definition, CRPMetS identifies more people at risk than MetS but still maintains a similar mortality risk. Incorporating CRP into the definition for MetS may be useful in identifying additional high-risk populations to target for prevention.

Original languageEnglish (US)
Pages (from-to)2284-2290
Number of pages7
JournalDiabetes care
Volume37
Issue number8
DOIs
StatePublished - Aug 2014

Fingerprint

C-Reactive Protein
Stroke
Mortality
Adenosine Triphosphate
Population
hydroquinone
Health Services Needs and Demand
Protein C
Proportional Hazards Models
Observational Studies
Cohort Studies
Research Design
Odds Ratio
Cholesterol
Therapeutics

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Metabolic syndrome, C-reactive protein, and mortality in U.S. blacks and whites : The reasons for geographic and racial differences in Stroke (REGARDS) study. / Suzuki, Takeki; Voeks, Jenifer; Zakai, Neil A.; Jenny, Nancy Swords; Brown, Todd M.; Safford, Monika M.; LeWinter, Martin; Howard, George; Cushman, Mary.

In: Diabetes care, Vol. 37, No. 8, 08.2014, p. 2284-2290.

Research output: Contribution to journalArticle

Suzuki, Takeki ; Voeks, Jenifer ; Zakai, Neil A. ; Jenny, Nancy Swords ; Brown, Todd M. ; Safford, Monika M. ; LeWinter, Martin ; Howard, George ; Cushman, Mary. / Metabolic syndrome, C-reactive protein, and mortality in U.S. blacks and whites : The reasons for geographic and racial differences in Stroke (REGARDS) study. In: Diabetes care. 2014 ; Vol. 37, No. 8. pp. 2284-2290.
@article{caace7b78c284d91840a8fb4831aeff1,
title = "Metabolic syndrome, C-reactive protein, and mortality in U.S. blacks and whites: The reasons for geographic and racial differences in Stroke (REGARDS) study",
abstract = "OBJECTIVE: We evaluate associations of metabolic syndrome (MetS), C-reactive protein (CRP), and a CRP-incorporated definition of MetS (CRPMetS) with risk of all-cause mortality in a biracial population. RESEARCH DESIGN AND METHODS: We studied 23,998 participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort, an observational study of black and white adults ≥45 years old across the U.S. Elevated CRP was defined as ≥3 mg/L and MetS by therevised Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III; ATP III) criteria (three of five components). CRPMetS was defined as presence of three out of six components, with elevated CRP added to ATP III criteria as a sixth component. Cox models were used to calculate hazard ratios (HRs) for all-cause mortality, and population attributable risk (PAR) was calculated. Stratified analyses based on race and diabetes status were performed. RESULTS: There were 9,741 participants (41{\%}) with MetS and 12,179 (51{\%}) with CRPMetS at baseline. Over 4.8 years of follow-up, 2,050 participants died. After adjustment for multiple confounders, MetS, elevated CRP, and CRPMetS were each significantly associated with increased mortality risk (HRs 1.26 [95{\%} CI 1.15-1.38], 1.55 [1.41-1.70], and 1.34 [1.22-1.48], respectively). The PAR was 9.5{\%} for MetS, 18.1{\%} for CRP, and 14.7{\%} for CRPMetS. Associations of elevated CRP and of CRPMetS with mortality were significantly greater in whites than blacks, while no differences in associations were observed based on diabetes status. CONCLUSIONS: By definition, CRPMetS identifies more people at risk than MetS but still maintains a similar mortality risk. Incorporating CRP into the definition for MetS may be useful in identifying additional high-risk populations to target for prevention.",
author = "Takeki Suzuki and Jenifer Voeks and Zakai, {Neil A.} and Jenny, {Nancy Swords} and Brown, {Todd M.} and Safford, {Monika M.} and Martin LeWinter and George Howard and Mary Cushman",
year = "2014",
month = "8",
doi = "10.2337/dc13-2059",
language = "English (US)",
volume = "37",
pages = "2284--2290",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "8",

}

TY - JOUR

T1 - Metabolic syndrome, C-reactive protein, and mortality in U.S. blacks and whites

T2 - The reasons for geographic and racial differences in Stroke (REGARDS) study

AU - Suzuki, Takeki

AU - Voeks, Jenifer

AU - Zakai, Neil A.

AU - Jenny, Nancy Swords

AU - Brown, Todd M.

AU - Safford, Monika M.

AU - LeWinter, Martin

AU - Howard, George

AU - Cushman, Mary

PY - 2014/8

Y1 - 2014/8

N2 - OBJECTIVE: We evaluate associations of metabolic syndrome (MetS), C-reactive protein (CRP), and a CRP-incorporated definition of MetS (CRPMetS) with risk of all-cause mortality in a biracial population. RESEARCH DESIGN AND METHODS: We studied 23,998 participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort, an observational study of black and white adults ≥45 years old across the U.S. Elevated CRP was defined as ≥3 mg/L and MetS by therevised Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III; ATP III) criteria (three of five components). CRPMetS was defined as presence of three out of six components, with elevated CRP added to ATP III criteria as a sixth component. Cox models were used to calculate hazard ratios (HRs) for all-cause mortality, and population attributable risk (PAR) was calculated. Stratified analyses based on race and diabetes status were performed. RESULTS: There were 9,741 participants (41%) with MetS and 12,179 (51%) with CRPMetS at baseline. Over 4.8 years of follow-up, 2,050 participants died. After adjustment for multiple confounders, MetS, elevated CRP, and CRPMetS were each significantly associated with increased mortality risk (HRs 1.26 [95% CI 1.15-1.38], 1.55 [1.41-1.70], and 1.34 [1.22-1.48], respectively). The PAR was 9.5% for MetS, 18.1% for CRP, and 14.7% for CRPMetS. Associations of elevated CRP and of CRPMetS with mortality were significantly greater in whites than blacks, while no differences in associations were observed based on diabetes status. CONCLUSIONS: By definition, CRPMetS identifies more people at risk than MetS but still maintains a similar mortality risk. Incorporating CRP into the definition for MetS may be useful in identifying additional high-risk populations to target for prevention.

AB - OBJECTIVE: We evaluate associations of metabolic syndrome (MetS), C-reactive protein (CRP), and a CRP-incorporated definition of MetS (CRPMetS) with risk of all-cause mortality in a biracial population. RESEARCH DESIGN AND METHODS: We studied 23,998 participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort, an observational study of black and white adults ≥45 years old across the U.S. Elevated CRP was defined as ≥3 mg/L and MetS by therevised Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III; ATP III) criteria (three of five components). CRPMetS was defined as presence of three out of six components, with elevated CRP added to ATP III criteria as a sixth component. Cox models were used to calculate hazard ratios (HRs) for all-cause mortality, and population attributable risk (PAR) was calculated. Stratified analyses based on race and diabetes status were performed. RESULTS: There were 9,741 participants (41%) with MetS and 12,179 (51%) with CRPMetS at baseline. Over 4.8 years of follow-up, 2,050 participants died. After adjustment for multiple confounders, MetS, elevated CRP, and CRPMetS were each significantly associated with increased mortality risk (HRs 1.26 [95% CI 1.15-1.38], 1.55 [1.41-1.70], and 1.34 [1.22-1.48], respectively). The PAR was 9.5% for MetS, 18.1% for CRP, and 14.7% for CRPMetS. Associations of elevated CRP and of CRPMetS with mortality were significantly greater in whites than blacks, while no differences in associations were observed based on diabetes status. CONCLUSIONS: By definition, CRPMetS identifies more people at risk than MetS but still maintains a similar mortality risk. Incorporating CRP into the definition for MetS may be useful in identifying additional high-risk populations to target for prevention.

UR - http://www.scopus.com/inward/record.url?scp=84904988781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904988781&partnerID=8YFLogxK

U2 - 10.2337/dc13-2059

DO - 10.2337/dc13-2059

M3 - Article

C2 - 24879838

AN - SCOPUS:84904988781

VL - 37

SP - 2284

EP - 2290

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 8

ER -